Clinical trial
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
NCT00326664 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 31, 2006
- Completion date
- July 31, 2015
- Enrollment
- 55 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.
childhood atypical teratoid/rhabdoid tumor, childhood central nervous system germ cell tumor, childhood cerebral anaplastic astrocytoma, childhood cerebral astrocytoma, childhood grade i meningioma, childhood grade ii meningioma, childhood grade iii meningioma, childhood infratentorial ependymoma, childhood oligodendroglioma, childhood spinal cord neoplasm, childhood supratentorial ependymoma, recurrent childhood brain neoplasm, recurrent childhood brain stem glioma, recurrent childhood cerebellar astrocytoma, recurrent childhood cerebral astrocytoma, recurrent childhood ependymoma, recurrent childhood medulloblastoma, recurrent childhood pineoblastoma, recurrent childhood subependymal giant cell astrocytoma, recurrent childhood supratentorial primitive neuroectodermal tumor, recurrent childhood visual pathway glioma